An Analysis Of Nivolumab-Mediated Adverse Events And Association With Clinical Efficacy In Resected Stage Iii Or Iv Melanoma (Checkmate 238).
Mario Mandalà,James M.G. Larkin,Paolo Antonio Ascierto,Michele Del Vecchio,Helen Gogas,C. Lance Cowey,Ana Maria Arance Fernandez,Stéphane Dalle,Michael Schenker,Jean Jacques Grob,Vanna Chiarion-Sileni,Ivan Marquez-Rodas,Marcus Butler,Anna Maria Di Giacomo,Mark R. Middleton,Jose Lutzky,Michael Millward,Veerle de Pril,Maurice Lobo,Jeffrey S. Weber JOURNAL OF CLINICAL ONCOLOGY（2019）
AI 理解论文
溯源树
样例
